查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1643920

全球麸质不耐症治疗市场 - 2025-2032

Global Gluten Intolerance Treatment Market - 2025-2032
出版日期: | 出版商: DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024年，全球麸质不耐症治疗市场规模达66.3亿美元，预计2032年将达到161.8亿美元，2024-2032年预测期间复合年增长率为11.8%。

麸质不耐症，也称为非乳糜泻麸质敏感性，是指个体在食用含麸质食物后出现腹部不适、腹胀和疲劳等症状，但没有患有乳糜泻或小麦过敏的情况。与乳糜泻不同，麸质不耐症不会对小肠造成损害，但仍会导致严重不适并影响生活品质。

麸质不耐症治疗市场包括旨在缓解症状和改善消化的治疗方法，包括膳食补充剂、酵素疗法和新兴药物选择。随着越来越多的人意识到麸质不耐症及其症状，支持性治疗和管理解决方案的市场正在扩大。

市场动态：

驱动程式和限制

麸质不耐症的诊断率不断提高

诊断率的提高预计将导致更多的患者寻求医疗干预，从而推动麸质不耐症治疗市场的发展。随着医疗保健提供者和公众对麸质不耐症和乳糜泻的认识不断增强，越来越多的人得到了准确诊断。诊断数量的增加意味着对有效治疗方案的更大需求，例如酵素疗法、补充剂和新兴药物疗法。

此外，越来越多的确诊患者正在积极寻求除严格的无麸质饮食之外的控制病情的解决方案，这推动了支持性治疗市场的发展。随着确诊病例数持续上升，麸质不耐症治疗的市场可能会大幅扩大。

饮食偏好和非医疗方法

饮食偏好和非医疗方法预计将阻碍麸质不耐症治疗市场，因为许多人更喜欢透过无麸质饮食来控制自己的病情，而不是依赖药物干预。无麸质饮食被广泛认为是控制症状的主要且最有效的方法，这使得许多患者不太愿意寻求额外的治疗，例如酵素补充剂或药物。这种对饮食管理的依赖限制了市场对药物治疗的需求。

此外，个人可能认为非医疗方法（例如生活方式的改变）足以控制他们的病情，降低新疗法的紧迫性，从而减缓市场成长。

目录

第 1 章：方法与范围

第 2 章：定义与概述

第 3 章：执行摘要

第 4 章：动力学

  • 影响因素
    • 司机
      • 麸质不耐症的诊断率不断提高
    • 限制
      • 饮食偏好和非医疗方法
    • 机会
    • 影响分析

第 5 章：产业分析

  • 波特五力分析
  • 供应链分析
  • 定价分析
  • 专利分析
  • 监管分析
  • SWOT分析
  • 未满足的需求

第 6 章：按治疗类型

  • 饮食管理
  • 药品
  • 营养补充品
  • 其他的

第 7 章：按治疗类型

  • 儿科
  • 成人
  • 老年科

第 8 章：按配方

  • 平板电脑
  • 粉末
  • 液体

第 9 章：按配销通路

  • 网路药局
  • 零售药局
  • 电子商务

第 10 章：按地区

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第 11 章：竞争格局

  • 竞争场景
  • 市场定位/份额分析
  • 併购分析

第 12 章：公司简介

  • DSM-Firmenich
    • 公司概况
    • 产品组合
      • 产品描述
      • 产品关键绩效指标 (KPI)
      • 历史和预测产品销售
      • 产品销售
    • 财务概览
      • 公司收入
      • 地域收入份额
      • 收入预测
    • 主要进展
      • 併购
      • 主要产品开发活动
      • 监管部门批准等
    • SWOT分析
  • Genetic Nutrition
  • NOW Foods
  • Enzymedica
  • AMYRA Biotech AG
  • KLAIRE LABS
  • Precigen
  • Takeda Pharmaceutical Company Limited
  • Similar data will be provided for each market player.

第 13 章：附录

简介目录
Product Code: PH9054

The global gluten intolerance treatment market reached US$ 6.63 billion in 2024 and is expected to reach US$ 16.18 billion by 2032, growing at a CAGR of 11.8% during the forecast period 2024-2032.

Gluten intolerance, also known as non-celiac gluten sensitivity, is a condition where individuals experience symptoms such as abdominal discomfort, bloating, and fatigue after consuming gluten-containing foods, without having celiac disease or a wheat allergy. Unlike celiac disease, gluten intolerance does not cause damage to the small intestine but can still lead to significant discomfort and impact quality of life.

The gluten intolerance treatment market encompasses treatments aimed at alleviating symptoms and improving digestion, including dietary supplements, enzyme therapies, and emerging pharmaceutical options. As more people become aware of gluten intolerance and its symptoms, the market for supportive treatments and management solutions is expanding.

Market Dynamics: Drivers & Restraints

Growing Diagnosis Rates of Gluten-intolerance

Increasing diagnosis rates are expected to drive the gluten intolerance treatment market by leading to a larger patient population seeking medical interventions. As awareness of gluten intolerance and celiac disease grows among both healthcare providers and the public, more individuals are being accurately diagnosed. This rise in diagnoses translates to greater demand for effective treatment options, such as enzyme therapies, supplements, and emerging drug therapies.

Additionally, more diagnosed individuals are actively seeking solutions to manage their condition beyond a strict gluten-free diet, fueling the market for supportive treatments. As the number of diagnosed cases continues to rise, the market for gluten intolerance treatments is likely to expand significantly.

Dietary Preferences and Non-Medical Approaches

Dietary preferences and non-medical approaches are expected to hinder the gluten intolerance treatment market as many individuals prefer managing their condition through a gluten-free diet rather than relying on pharmaceutical interventions. The gluten-free diet is widely considered the primary and most effective way to control symptoms, which makes many patients less inclined to seek additional treatments such as enzyme supplements or medications. This reliance on dietary management limits the market demand for medical therapies.

Additionally, individuals may feel that non-medical approaches, such as lifestyle changes, are sufficient to manage their condition, reducing the urgency for new treatments and thus slowing market growth.

Segment Analysis

The global gluten intolerance treatment market is segmented based on treatment type, patient type, formulation, distribution channel, and region.

Type:

Nutritional supplements segment is expected to dominate the global gluten intolerance treatment market share

Nutritional supplements are expected to dominate the gluten intolerance treatment market due to their accessibility and growing popularity among patients seeking to manage symptoms alongside a gluten-free diet. Products like enzyme supplements and probiotics are gaining traction as they offer a convenient, non-invasive option to alleviate discomfort from accidental gluten exposure. Companies are focusing on developing these products which are increasingly gaining traction due to their increased safety and efficacy. For instance, in October 2024, AMYRA Biotech AG announced the peer-reviewed publication of its clinical proof-of-principle study with its lead product AMYNOPEP. AMYNOPEP is the first and only gluten-digesting enzyme combination that supports and enhances the activity of critical endogenous enzymes on the lining of the small intestine.

With increasing consumer awareness of the benefits of such supplements, the demand for these products is expanding, as they provide additional support without the need for prescription drugs. This trend positions nutritional supplements as a key segment in the market, driven by their ability to offer symptom relief and improve overall gut health for individuals with gluten intolerance.

Geographical Analysis

North America is expected to hold a significant position in the global gluten intolerance treatment market share

North America is expected to dominate the gluten intolerance treatment market due to high awareness, advanced healthcare infrastructure, and a large consumer base actively seeking treatment options. The U.S., in particular, leads in both diagnosis rates and adoption of gluten intolerance treatments, with a growing number of patients opting for enzyme supplements and emerging therapies.

Additionally, the presence of key pharmaceutical companies and the increasing availability of gluten-free products and treatments further strengthen North America's market share. The rising expansion of product availability in the region with rising innovative products is expected to contribute to the market growth in the region. For instance, in December 2024 GluteGuard, the first and only clinically proven product in Canada that helps to protect against the symptoms of accidental gluten ingestion is made available across the country. With the expansion of product expansion in the region, the market is expected to grow which contributes to the overall market growth. As awareness of gluten intolerance continues to rise, the region is likely to maintain its dominance in the treatment market.

Competitive Landscape

The major global players in the gluten intolerance treatment market include DSM-Firmenich, Genetic Nutrition, NOW Foods, Enzymedica, AMYRA Biotech AG, KLAIRE LABS, Precigen and Takeda Pharmaceutical Company Limited among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global Gluten Intolerance Treatment Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Treatment Type
  • 3.2. Snippet by Patient Type
  • 3.3. Snippet by Formulation
  • 3.4. Snippet by Distribution Channel
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing Diagnosis Rates of Gluten-intolerance
    • 4.1.2. Restraints
      • 4.1.2.1. Dietary Preferences and Non-Medical Approaches
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Patent Analysis
  • 5.5. Regulatory Analysis
  • 5.6. SWOT Analysis
  • 5.7. Unmet Needs

6. By Treatment Type

  • 6.1. Introduction
    • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 6.1.2. Market Attractiveness Index, By Treatment Type
  • 6.2. Dietary Management*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Pharmaceuticals
  • 6.4. Nutritional Supplements
  • 6.5. Others

7. By Treatment Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 7.1.2. Market Attractiveness Index, By Treatment Type
  • 7.2. Pediatric*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Adult
  • 7.4. Geriatric

8. By Formulation

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Formulation
    • 8.1.2. Market Attractiveness Index, By Formulation
  • 8.2. Tablets*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Powders
  • 8.4. Liquid

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Online Pharmacies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Retail Pharmacies
  • 9.4. E-Commerce

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Formulation
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.7.1. U.S.
      • 10.2.7.2. Canada
      • 10.2.7.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Formulation
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.7.1. Germany
      • 10.3.7.2. U.K.
      • 10.3.7.3. France
      • 10.3.7.4. Spain
      • 10.3.7.5. Italy
      • 10.3.7.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Formulation
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.7.1. Brazil
      • 10.4.7.2. Argentina
      • 10.4.7.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Formulation
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. South Korea
      • 10.5.7.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Formulation
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

Key Market Players

  • 12.1. DSM-Firmenich*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio
      • 12.1.2.1. Product Description
      • 12.1.2.2. Product Key Performance Indicators (KPIs)
      • 12.1.2.3. Historic and Forecasted Product Sales
      • 12.1.2.4. Product Sales Volume
    • 12.1.3. Financial Overview
      • 12.1.3.1. Company Revenue's
      • 12.1.3.2. Geographical Revenue Shares
      • 12.1.3.3. Revenue Forecasts
    • 12.1.4. Key Developments
      • 12.1.4.1. Mergers & Acquisitions
      • 12.1.4.2. Key Product Development Activities
      • 12.1.4.3. Regulatory Approvals etc.
    • 12.1.5. SWOT Analysis
  • 12.2. Genetic Nutrition
  • 12.3. NOW Foods
  • 12.4. Enzymedica
  • 12.5. AMYRA Biotech AG
  • 12.6. KLAIRE LABS
  • 12.7. Precigen
  • 12.8. Takeda Pharmaceutical Company Limited
  • Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us